Neopterin and asymmetric dimethylarginine levels in patients with type 2 diabetic retinopathy

Alpaslan Karabulut; Tayfun Şahin; Mustafa Şahin

doi:10.5281/zenodo.8011560

Authors

Alpaslan Karabulut
Tayfun Şahin
Mustafa Şahin

DOI:

https://doi.org/10.5281/zenodo.8011560

Keywords:

Asymmetric dimethyl arginine, diabetic retinopathy, neopterin

Abstract

Objective: We aimed at determining the relationship between asymmetric dimethyl arginine (ADMA) and neopterin levels and diabetic retinopathy (DR) in type 2 diabetes mellitus (T2DM).

Materials and methods: In our study, we included 41 T2DM patients with DR, 21 T2DM patients without DR, and 20 healthy controls. We measured HbA1c, fasting blood glucose, creatinine, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, neutrophil-lymphocyte ratio, neopterin, and ADMA levels by taking fasting serum and plasma samples. In healthy controls, we evaluated ADMA and neopterin levels in T2DM patients with DR, and T2DM patients without DR. We evaluated the relationship between ADMA levels and HbA1c, fasting blood glucose, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and neopterin.

Results: There was no statistically significant difference in ADMA and neopterin levels between the DR group, the non-DR group, and the control group. There was no significant relationship found between ADMA and neopterin levels and the severity of retinopathy.In our study, we only found a moderate positive correlation between ADMA and neopterin (ρ=0.453 p<0.001).

Conclusions: Serum ADMA and neopterin levels did not differ significantly between groups at all stages of DR. Regardless of macrovascular disease, we think that serum neopterin and ADMA levels are not associated with retinopathy in patients with T2DM. Further studies are needed to determine whether ADMA and neopterin have an effect on the pathogenesis.

References

Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703-13.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.

de Moraes R, Van Bavel D, Gomes MB, Tibiriçá E. Effects of non-supervised low intensity aerobic excise training on the microvascular endothelial function of patients with type 1 diabetes: a non-pharmacological interventional study. BMC Cardiovasc Disord. 2016;16:23.

Tousoulis D, Georgakis MK, Oikonomou E, Papageorgiou N, Zaromitidou M, Latsios G, et al. Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches. Curr Med Chem. 2015;22(24):2871-901.

Yuan Q, Hu CP, Gong ZC, Bai YP, Liu SY, Li YJ, et al. Accelerated onset of senescence of endothelial progenitor cells in patients with type 2 diabetes mellitus: role of dimethylarginine dimethylaminohydrolase 2 and asymmetric dimethylarginine. Biochem Biophys Res Commun. 2015;458(4):869-76.

Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2007;30(7):1834-9.

Domingueti CP, Dusse LM, Carvalho Md, de Sousa LP, Gomes KB, Fernandes AP. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications. 2016;30(4):738-45.

Kawata T, Daimon M, Hasegawa R, Teramoto K, Toyoda T, Sekine T, et al. Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus. Int J Cardiol. 2009;132(2):286-8.

Yang TL, Chen MF, Luo BL, Xie QY, Jiang JL, Li YJ. Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedebergs Arch Pharmacol. 2005;371(5):401-7.

Eisenhut M. Neopterin in Diagnosis and Monitoring of Infectious Diseases. J Biomark. 2013;2013:196432.

Widner B, Leblhuber F, Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson’s disease. J Neural Trans 2002;109(2):181– 9.

De Rosa S, Cirillo P, Pacileo M, Petrillo G, D'Ascoli GL, Maresca F, et al. Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology. Curr Vasc Pharmacol. 2011;9(2):188-99.

Kumar, A. Zhang, K. Targeting Chitin-Containing Organisms. Human Chitinases: Structure, Function, and Inhibitor Discovery; Springer: Singapore, 2019; pp. 5–18.

Ganjee R, Azmi R, Moghadam ME. A Novel Microaneurysms Detection Method Based on Local Applying of Markov Random Field. J Med Syst. 2016;40(3):74.

R.N. Frank, Diabeticretinopathy, N Eng J Med 2004;350:48–58.

Erbil MK, Kurt YG, Yaman H, Çakır E, Akgül EÖ, Çaycı T. Metabolism of asymmetric dimethylarginine and its clinical significance Turk J Biochem 2012;37(1):99–105.

Abhary S, Kasmeridis N, Burdon KP, Kuot A, Whiting MJ, Yew WP, et al. Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines. Diabetes Care. 2009;32(11):2084-6.

Malecki MT, Undas A, Cyganek K, Mirkiewicz-Sieradzka B, Wolkow P, Osmenda G, et al. Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type 2 diabetes. Diabetes Care. 2007 Nov;30(11):2899-901.

Yuan CM, Nee R, Ceckowski KA, Knight KR, Abbott KC. Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center. Clin Kidney J. 2017;10(2):257-262.

Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30(1):49-59.

Mihout F, Shweke N, Bigé N, Jouanneau C, Dussaule JC, Ronco P, et al. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis. J Pathol. 2011;223(1):37-45.

Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care. 2004;27(3):765-9.

Yonem A, Duran C, Unal M, Ipcioglu OM, Ozcan O. Plasma apelin and asymmetric dimethylarginine levels in type 2 diabetic patients with diabetic retinopathy. Diabetes Res Clin Pract. 2009;84(3):219-23.

Krzyzanowska K, Mittermayer F, Schernthaner GH, Brunner S, Brix JM, Aschauer S, et al. Renal function but not asymmetric dimethylarginine is independently associated with retinopathy in type 2 diabetes. Cardiol Res Pract. 2011;2011:260191.

Sugai M, Ohta A, Ogata Y, Nakanishi M, Ueno S, Kawata T, et al. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr J. 2007;54(2):303-9.

Avci E, Coskun S, Cakir E, Kurt Y, Ozgur Akgul E, Bilgi C. Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients. Ren Fail. 2008;30(8):784-90.

Siasos G, Tousoulis D, Antoniades C, Stefanadi E, Stefanadis C. L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis? Int J Cardiol. 2007;116(3):300-8.

Collinson P. Laboratory Medicine is Faced with the Evolution of Medical Practice. J Med Biochem. 2017;36(3):211-5.

Avci E, Karabulut A, Alp AG, Baba B, Bilgi C. Crucial markers showing the risk of coronary artery disease in obesity: ADMA and neopterin. J Med Biochem. 2020;39(4):452-9.

Anwaar I, Gottsäter A, Eriksson K, Jacobsson L, Lindgärde F, Mattiasson I. Increased plasma endothelin-1 and intraplatelet cyclic guanosine monophosphate in men with disturbed glucose metabolism. Diabetes Res Clin Pract. 2000;50(2):127-36.

Cutaș A, Drugan C, Roman G, Rusu A, Cătană CS, Achimaș-Cadariu A, et al. Evaluation of Chitotriosidase and Neopterin as Biomarkers of Microvascular Complications in Patients with Type 1 Diabetes Mellitus. Diagnostics (Basel). 2021;11(2):263.